**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 59288

**Manuscript Type:** CASE REPORT

**Tuberous sclerosis patient with neuroendocrine carcinoma of the esophagogastric junction: A case report**

Ishida N *et al*. EG junction NEC with tuberous sclerosis

Natsuki Ishida, Takahiro Miyazu, Satoshi Tamura, Satoshi Suzuki, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Satoshi Osawa, Yasushi Hamaya, Kazuya Shinmura, Haruhiko Sugimura, Katsutoshi Miura, Takahisa Furuta, Ken Sugimoto

**Natsuki Ishida, Takahiro Miyazu, Satoshi Tamura, Mihoko Yamade, Yasushi Hamaya, Ken Sugimoto,** First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan

**Satoshi Suzuki, Shinya Tani, Satoshi Osawa,** Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan

**Moriya Iwaizumi,** Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan

**Kazuya Shinmura, Haruhiko Sugimura,** Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan

**Katsutoshi Miura,** Department of Health Science, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan

**Takahisa Furuta,** Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan

**Author contributions:** Ishida N and Sugimoto K wrote the manuscript; Miyazu T, Tamura S, Suzuki S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, and Furuta T contributed to the manuscript design and coordination; Shinmura K, Sugimura H, and Miura K contributed to the pathological examination.

**Corresponding author: Ken Sugimoto, MD, PhD, Associate Professor,** First Department of Medicine, Hamamatsu University School of Medicine, 1-20-1, Handayama, Hamamatsu 431-3192, Japan. sugimken@hama-med.ac.jp

**Received:** September 3, 2020

**Revised:** November 9, 2020

**Accepted:** November 14, 2020

**Published online:**

**Abstract**

BACKGROUND

Tuberous sclerosis complex (TSC) is a rare inherited disease with non-cancerous tumor growths in the skin, brain, kidneys, heart, and lungs. The co-occurrence of neuroendocrine neoplasm (NEN) with TSC is even rarer. There have been few reports on the relationship between TSC and neuroendocrine tumors (NETs), and fewer on the relationship between TSC and neuroendocrine carcinoma (NEC), a subtype of NEN. This is the first reported case of NEC occurring at the esophagogastric junction in a patient with TSC.

CASE SUMMARY

A 46-year-old woman visiting our hospital for the treatment of TSC was admitted to the emergency department with tarry stools and dizziness. Computed tomography scans revealed thickness of the gastric cardia, multiple metastatic lesions of the liver, and enlarged lymph nodes near the lesser curvature of the stomach. Esophagogastroduodenoscopy revealed a type 3 tumor located from the esophagogastric junction to the fundus, and the pathological diagnosis by biopsy was NEC. The patient was treated with seven courses of cisplatin + irinotecan, followed by eight courses of ramucirumab + nab-paclitaxel, one course of nivolumab, and two courses of S-1 + oxaliplatin. Twenty-three months after the first treatment, the patient died because of disease progression and deterioration of the general condition.

CONCLUSION

This case of NEC occurring in a patient with TSC indicates a difference in the occurrence of NETs and NECs.

**Key Words:** Tuberous sclerosis complex; Neuroendocrine carcinoma; Neuroendocrine tumor; mTOR inhibitor; Esophagogastric junction; Chemotherapy; Case report

Ishida N, Miyazu T, Tamura S, Suzuki S, Tani S, Yamade M, Iwaizumi M, Osawa S, Hamaya Y, Shinmura K, Sugimura H, Miura K, Furuta T, Sugimoto K. Tuberous sclerosis patient with neuroendocrine carcinoma of the esophagogastric junction: A case report. *World J Gastroenterol* 2020; In press

**Core Tip:** Although it has been reported that neuroendocrine tumors can merge with the tuberous sclerosis complex (TSC), the co-occurrence of neuroendocrine carcinoma (NEC) with TSC is rare. This is the first reported case of NEC occurring at the esophagogastric junction in a patient with TSC. This highly suggestive case indicates there is a difference in the occurrence of neuroendocrine tumors and NECs, which depends upon the pathogenesis of TSC developed despite inhibition of the AKT/mTOR pathway.

**INTRODUCTION**

Tuberous sclerosis complex (TSC) is a rare, dominant inherited disease with non-cancerous tumor growths in the skin, brain, kidneys, heart, and lungs, and it is caused by abnormalities in the tumor suppressor genes, *TSC1* and *TSC2*[1]. *TSC1* and *TSC2* produce proteins that regulate the intracellular mTOR pathway activity, and the loss of mTOR regulation owing to the abnormalities in these genes is thought to cause many of the symptoms of TSC. In addition, the mTOR pathway is significantly involved in the development of neuroendocrine tumors (NETs), and the mTOR inhibitor, everolimus, is known to be a therapeutic agent for NET[2].

Neuroendocrine carcinoma (NEC) is a subtype of neuroendocrine neoplasm (NEN), and NEC in the digestive tract is rare. Furthermore, NEC that occurs in the esophagus accounts for only 0.4% of all esophageal carcinomas[3]. There are quite a few detailed case reports regarding NEC occurring at the esophagogastric junction, and there are no reported cases of NEC at the esophagogastric junction with TSC as the underlying disease[4–8].

We, therefore, report an extremely rare case of TSC, which is considered to have an abnormality in the mTOR pathway, co-occurring with NEC.

**CASE PRESENTATION**

***Chief complaints***

A 43-year-old woman visited the emergency room of our hospital complaining of tarry stool and dizziness.

***History of present illness***

The patient’s symptoms started the previous day before visiting the emergency room.

***History of past illness***

The patient has a history of TSC, facial angiofibroma, seizure, renal angiofibroma, and lymphangioleiomyomatosis (LAM). She was administered sirolimus, which is an mTOR inhibitor, for the treatment of LAM.

***Physical examination***

On physical examination at the time of hospitalization, her heart rate was 113 beats per minute, and her blood pressure was 95/72 mmHg. The liver, spleen, and tumor were not palpable on physical examination.

***Laboratory examinations***

Laboratory examination revealed decreased hemoglobin levels (12.6 g/dL) and elevated carcinoembryonic antigen (41.2 ng/mL), carbohydrate antigen 19-9 (80 pg/mL), and neuron-specific enolase levels (56.0 ng/mL). Pro-gastrin-releasing peptide level was within the normal limits (40.7 pg/mL).

***Imaging examinations***

Computed tomography (CT) scans showed wall thickness from the esophagogastric junction to the gastric cardia. Enlarged lymph nodes near the lesser curvature of the stomach and multiple space-occupying, ring-enhancing metastatic lesions in the liver were observed (Figure 1). Gastric endoscopy revealed a type 3 tumor located from the esophagogastric junction to the gastric cardia (Figure 2). The bleeding from the lesion was the cause of the tarry stool, and the patient was then hospitalized and treated with a proton pump inhibitor.

**FINAL DIAGNOSIS**

The pathological diagnosis based on a biopsy of a mucosal lesion was NEC (Figure 3). Hematoxylin and eosin (H-E) staining showed atypical epithelial cells forming solid nests with a high nucleocytoplasmic ratio. Tests for immunohistological markers CD56, synaptophysin, and chromogranin A were positive, and the Ki 67 index was approximately 70%. Based on the above results, the patient was diagnosed with esophagogastric neuroendocrine carcinoma T3, N1, M1, Stage IVB (AJCC/UICC 8th edition[9]).

**TREATMENT**

Since the tumor was clinical stage IV and inoperable, cisplatin (CDDP) + irinotecan (CPT-11) therapy was selected for chemotherapy. The eligible regimen for this patient included cisplatin (60 mg/m2, day 1) and irinotecan (60 mg/m2, day 1, 8, and 15). However, the first cisplatin dose was reduced to 48 mg/m2 (80% dose) because of renal failure due to renal angiomyolipoma. The patient experienced grade 2 neutropenia as a side effect after the first course of chemotherapy; irinotecan dose was then reduced to 48 mg/m2 (80% dose). A CT scan after seven courses of chemotherapy revealed increased liver metastasis. Serum tumor markers were elevated and disease progression was observed (Figure 4). As a second-line regimen, ramucirumab (RAM) and nab-paclitaxel (nab-PTX) therapy were administered to this patient. The eligible regimen was ramucirumab (8 mg/kg, day 1 and 15) and paclitaxel (80 mg/m2, day 1, 8, and 15). During the eight courses of the second-line chemotherapy, although the patient had no remarkable adverse events, another liver metastasis occurred. Nivolumab was administered as a third-line regimen. However, after one course of treatment, a further increase in tumor markers was observed and liver metastases worsened. As a fourth-line therapy, the S-1 + oxaliplatin regimen was administered to the patient.

**OUTCOME AND FOLLOW-UP**

After two courses of chemotherapy, owing to the exacerbation of NEC, the patient died 23 mo after the first diagnosis. The pathological autopsy was performed with the consent of the patient's family. In addition to multiple liver and lymph node metastases previously identified by CT examination, lung, adrenal, spleen, and kidney metastases, and peritoneal dissemination were observed.

**DISCUSSION**

The following three points are considered to have high clinical and academic value in this case: (1) NEC co-occurred with TSC, a rare disease; (2) although the patient was administered sirolimus, an mTOR inhibitor, against LAM, she developed NEC, which is a type of NEN; and (3) the patient was treated with multiple chemotherapy regimens for small-cell lung cancer and gastric cancer, and she survived for 23 mo after the diagnosis.

TSC is an inherited, autosomal, dominant, multisystem disorder characterized by the development of multiple hamartomas in neuron organs. It occurs in 1 in 6000 individuals[10], and approximately 60% of TSCs are sporadic cases. In our case, none of the family members of the patient had TSC. TSC is caused by mutations in two tumor suppressor genes, *TSC1* on chromosome 9q4 and *TSC2* on chromosome 16p13.3, which encode hamartin and tuberin, respectively. The mutation type in the patient was not examined. Owing to these gene mutations, TSC may affect the skin, central nervous system, kidney, heart, eye, blood vessels, lung, bone, and gastrointestinal tract. The *TSC1* and *TSC2* genes are involved in the AKT-mTOR pathway activation and are, therefore, involved in the development and proliferation of NETs. Previous studies have reported a relationship between TSC and NETs[11–13]. Gastrointestinal NEC is a type of NEN and is a poorly differentiated cancer with neuroendocrine characteristics classified by the 2019 World Health Organization tumor classification[14]. NEC is known to have a high degree of malignancy and rapid progression. In our case, metastases to various organs were found by pathological autopsy after death.

There are few reported cases on the complications of NETs and TSCs, and there are few reports on the complications of NECs and TSCs. Most of the reported cases of TSCs complicated with NETs have grade 1 or 2 NET[13]. Arva *et al*[11] presented a case of well-differentiated NEC of the pancreas in a child with TSC[11]. However, there are no reports of TSC patients with gastrointestinal tract NEC listed in PubMed from 1950 to 2020.

LAM is a rare neoplastic disease in which abnormal LAM cells resembling smooth muscle cells grow relatively slowly in the lungs, lymph nodes, and kidneys. LAM diagnosis is age dependent and occurs in up to 80% of women with TSC by the age of 40[15]. Recently, the effect of the mTOR inhibitor, sirolimus, on LAM was reported[16], and our patient was also administered sirolimus for LAM. In the AKT-mTOR pathway, mTOR inhibitor is thought to reduce protein translation and suppresses subsequent neuroendocrine tumor development (Figure 5)[12]. However, in our case, NEC developed despite the administration of an mTOR inhibitor.

The carcinogenesis of NEC was once argued for the mechanism of stem cell development and development derived from NETs. However, there are genetic differences in NECs that are not observed in NETs such as the overexpression of p53 protein, diffuse deficiency of retinoblastoma protein, and diffuse overexpression of p16 protein in highly malignant tumors. Therefore, NETs and NECs have been reported to be genetically different[17–19]. In our case, NEC developed while mTOR was inhibited by sirolimus, so it is speculated that this case may have followed the clinical course supported by this theory, because sirolimus could inhibit the development of NEC only if NETs and NECs were genetically similar.

The European Neuroendocrine Tumor Society guidelines recommend that chemotherapy for NEC is based on a small-cell lung cancer regimen[20–21]. The first-line therapy for small-cell lung cancer regimens is CDDP + CPT-11 or CDDP + etoposide (VP16), and retrospective studies in Japan have reported that these platinum-based chemotherapies have equivalent effects for NEC[22]. In our case, the CDDP + CPT-11 regimen, which is frequently administered in Japan, was administered. Since the initial pathological diagnosis suggested that adenocarcinoma might coexist with NETs, chemotherapy of RAM + nab-PTX for adenocarcinoma was selected as the second-line treatment. Although this case was finally diagnosed with NEC, the second-line chemotherapy was successful since the patient was able to continue eight courses of RAM + nab-PTX therapy. Some previous cases have reported the effectiveness of RAM + nab-PTX treatment for gastrointestinal tract NEC[23,24]. In the future, accumulation of RAM + nab-PTX administration cases for gastrointestinal tract NEC is expected.

**CONCLUSION**

We have reported NEC occurring at the esophagogastric junction in a patient with TSC. Considering the pathogenesis of TSC developed despite the inhibition of the AKT/mTOR pathway, it was a highly suggestive case indicating a difference in the occurrence of NETs and NECs. We also supported the possibility that a RAM + nab-PTX regimen was effective against gastrointestinal NEC.

**REFERENCES**

1 **Henske EP**, Jóźwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. *Nat Rev Dis Primers* 2016; **2**: 16035 [PMID: 27226234 DOI: 10.1038/nrdp.2016.35]

2 **Chan J**, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. *Curr Treat Options Oncol* 2014; **15**: 365-379 [PMID: 25092520 DOI: 10.1007/s11864-014-0294-4]

3 **Tachimori Y**, Ozawa S, Numasaki H, Ishihara R, Matsubara H, Muro K, Oyama T, Toh Y, Udagawa H, Uno T; Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Comprehensive Registry of Esophageal Cancer in Japan, 2011. *Esophagus* 2018; **15**: 127-152 [PMID: 29948477 DOI: 10.1007/s10388-018-0614-z]

4 **Veits L**, Lang-Schwarz C, Volkholz H, Falkeis C, Vieth M, Schulz H. Mixed adenoneuroendocrine carcinoma (MANEC) of the esophagogastric junction predominantly consisting of poorly differentiated neuroendocrine carcinoma. *Endoscopy* 2013; **45 Suppl 2 UCTN**: E16-E17 [PMID: 23468146 DOI: 10.1055/s-0032-1326113]

5 **Juanmartiñena JF**, Fernández-Urién I, Córdoba A, Miranda C, Borda A. Mixed adenoneuroendocrine carcinoma (MANEC) of the gastroesophageal junction: a case report and review of the literature. *Rev Esp Enferm Dig* 2017; **109**: 160-162 [PMID: 26999428 DOI: 10.17235/reed.2016.4315/2016]

6 **Ambesh P**, Weissbrot J, Ratner S, Sinha A, Patti R, Balderacchi J, Marcelin M, Wolf L, Kamholz S. Mixed Adenoneuroendocrine Carcinoma of the Gastroesophageal Junction: A Rare Find. *J Investig Med High Impact Case Rep* 2017; **5**: 2324709617750180 [PMID: 29318164 DOI: 10.1177/2324709617750180]

7 **Yamamoto M**, Ozawa S, Koyanagi K, Oguma J, Kazuno A, Ninomiya Y, Yatabe K, Hatanaka K. Mixed adenoneuroendocrine carcinoma of the esophagogastric junction: a case report. *Surg Case Rep* 2018; **4**: 56 [PMID: 29900476 DOI: 10.1186/s40792-018-0464-x]

8 **Mendoza-Moreno F**, Díez-Gago MR, Mínguez-García J, Tallón-Iglesias B, Zarzosa-Hernández G, Fernández S, Solana-Maoño M, Argüello-De-Andrés JM. Mixed Adenoneuroendocrine Carcinoma of the Esophagus: A Case Report and Review of the Literature. *Niger J Surg* 2018; **24**: 131-134 [PMID: 30283226 DOI: 10.4103/njs.NJS\_43\_17]

9 **Rice TW,** Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. *Ann Cardiothorac Surg* 2017; **6(2):** 119-130 [PMID: 28447000 DOI: 10.21037/acs.2017.03.14]

10 **Osborne JP**, Fryer A, Webb D. Epidemiology of tuberous sclerosis. *Ann N Y Acad Sci* 1991; **615**: 125-127 [PMID: 2039137 DOI: 10.1111/j.1749-6632.1991.tb37754.x]

11 **Arva NC**, Pappas JG, Bhatla T, Raetz EA, Macari M, Ginsburg HB, Hajdu CH. Well-differentiated pancreatic neuroendocrine carcinoma in tuberous sclerosis--case report and review of the literature. *Am J Surg Pathol* 2012; **36**: 149-153 [PMID: 22173120 DOI: 10.1097/PAS.0b013e31823d0560]

12 **Missiaglia E**, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce CM, Scarpa A. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. *J Clin Oncol* 2010; **28**: 245-255 [PMID: 19917848 DOI: 10.1200/JCO.2008.21.5988]

13 **Dworakowska D**, Grossman AB. Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. *Endocr Relat Cancer* 2009; **16**: 45-58 [PMID: 18978035 DOI: 10.1677/ERC-08-0142]

14 **Nagtegaal ID,** Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA; WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. *Histopathology* 2020; **76(2):** 182-188 [PMID: 31433515 DOI: 10.1111/his.13975]

15 **Adriaensen ME**, Schaefer-Prokop CM, Duyndam DA, Zonnenberg BA, Prokop M. Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex. *Clin Radiol* 2011; **66**: 625-628 [PMID: 21459371 DOI: 10.1016/j.crad.2011.02.009]

16 **McCormack FX**, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. *N Engl J Med* 2011; **364**: 1595-1606 [PMID: 21410393 DOI: 10.1056/NEJMoa1100391]

17 **Konukiewitz B**, Schlitter AM, Jesinghaus M, Pfister D, Steiger K, Segler A, Agaimy A, Sipos B, Zamboni G, Weichert W, Esposito I, Pfarr N, Klöppel G. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. *Mod Pathol* 2017; **30**: 587-598 [PMID: 28059098 DOI: 10.1038/modpathol.2016.217]

18 **Hijioka S**, Hosoda W, Matsuo K, Ueno M, Furukawa M, Yoshitomi H, Kobayashi N, Ikeda M, Ito T, Nakamori S, Ishii H, Kodama Y, Morizane C, Okusaka T, Yanagimoto H, Notohara K, Taguchi H, Kitano M, Yane K, Maguchi H, Tsuchiya Y, Komoto I, Tanaka H, Tsuji A, Hashigo S, Kawaguchi Y, Mine T, Kanno A, Murohisa G, Miyabe K, Takagi T, Matayoshi N, Yoshida T, Hara K, Imamura M, Furuse J, Yatabe Y, Mizuno N. Rb Loss and *KRAS* Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. *Clin Cancer Res* 2017; **23**: 4625-4632 [PMID: 28455360 DOI: 10.1158/1078-0432.CCR-16-3135]

19 **Yachida S**, Vakiani E, White CM, Zhong Y, Saunders T, Morgan R, de Wilde RF, Maitra A, Hicks J, Demarzo AM, Shi C, Sharma R, Laheru D, Edil BH, Wolfgang CL, Schulick RD, Hruban RH, Tang LH, Klimstra DS, Iacobuzio-Donahue CA. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. *Am J Surg Pathol* 2012; **36**: 173-184 [PMID: 22251937 DOI: 10.1097/PAS.0b013e3182417d36]

20 **Garcia-Carbonero R**, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla JB, Caplin M, O'Toole D, Perren A; Vienna Consensus Conference participants. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. *Neuroendocrinology* 2016; **103**: 186-194 [PMID: 26731334 DOI: 10.1159/000443172]

21 NCCN guidelines, version 2. 2018. Poorly differentiated neuroendocrine carcinoma/Large or small cell (other than lung) (PDNEC-1), 2018. Arrived from: <https://www.nccn.org/professionals/physician_gls/default.aspx>

22 **Yamaguchi T**, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K, Nishina T, Tobimatsu K, Ishido K, Furuse J, Boku N, Okusaka T. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. *Cancer Sci* 2014; **105**: 1176-1181 [PMID: 24975505 DOI: 10.1111/cas.12473]

23 **Motoo Y**. Ramucirumab Plus Paclitaxel: A Possible New Chemotherapy Regimen for Neuroendocrine Carcinoma of the Stomach. *Intern Med* 2018; **57**: 631-632 [PMID: 29151542 DOI: 10.2169/internalmedicine.9709-17]

24 **Matsubara Y**, Ando T, Hosokawa A, Mihara H, Takagi H, Nakata N, Yoshita H, Nanjo S, Kajiura S, Fujinami H, Sugiyama T. Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel. *Intern Med* 2018; **57**: 671-675 [PMID: 29151523 DOI: 10.2169/internalmedicine.9369-17]

**Footnotes**

**Informed consent statement:** The patient provided written informed consent.

**Conflict-of-interest statement:** The authors declare that there are no conflicts of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** September 3, 2020

**First decision:** November 3, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B



Grade C (Good): C

Grade D (Fair): 0



Grade E (Poor): 0

**P-Reviewer:** Cimen SG, Rodrigues AT **S-Editor:** Fan JR **L-Editor: P-Editor:**


**Figure Legends**


 


**Figure 1 Abdominal contrast-enhanced computed tomography images.** A: Wall thickness from the esophagogastric junction to the cardia (yellow arrowhead) and enlarged lymph nodes near the lesser curvature of the stomach (red arrow); B: Multiple ring-enhanced tumors are observed in the liver.


**Figure 2 Esophagogastroduodenoscopy revealed type 3 tumor located from the esophagogastric junction to the cardia.** A: Image from endoscopic examination of esophagus; B: Image from endoscopic examination of stomach.









**Figure 3 Histological findings of a mucosal lesion.** A: Low-power histological view of Hematoxylin and eosin (H-E) stained specimens showing atypical epithelial cells with solid alveolar nests; B: High-power view of H-E stained specimens reveals poorly differentiated atypical cells with large nucleus-cytoplasm ratio; C: Synaptophysin positive; D: Ki 67 index is approximately 70%; E: CD56 positive; F: Chromogranin A positive.





**Figure 4 Clinical course of this case.** CDDP: Cisplatin; CPT-11: Irinotecan; RAM: Ramucirumab; nab-PTX: Nab-Paclitaxel; NIVO: Nivolumab; SOX: S-1 and oxaliplatin; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; NSE: Neuron-specific enolase; Pro-GRP: Pro-gastrin-releasing peptide.



**Figure 5 Diagram showing that the mammalian target of rapamycin inhibitor suppresses the formation of neuroendocrine tumor by suppressing the AKT-mTOR pathway.** In the AKT-mTOR pathway, mutation of tuberous sclerosis complex *(TSC)1/TSC2* genes causes mTOR to proliferate and generate neuroendocrine tumor (NET). Sirolimus, an mTOR inhibitor, inhibits the abnormal growth of mTOR, which suppresses the generation of NET. TSC: Tuberous sclerosis complex; AMPK: Adenosine 5'-monophosphate (AMP)-activated protein kinase; ERK: Extracellular regulated protein kinases; RSK: Ribosomal S6 kinase; EBP: Evidence-based practice; NET: Neuroendocrine tumor.